
Biogen (BIIB) Stock Forecast & Price Target
Biogen (BIIB) Analyst Ratings
Bulls say
Biogen is a well-established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases. Its multiple sclerosis franchise, historically one of its key revenue generators, is facing competition, but is supported by collaborations with partners Roche and Eisai. Additionally, Biogen's newer franchises, including Spinraza, Leqembi, Skyclarys, Zurzuvae, and Qalsody, have promising data and strong potential in their respective indications. The company also has a strong pipeline with potential successes in rare kidney indications, CNS diseases, and oncology. Overall, the company's strong portfolio, promising pipeline, and clear focus on sustainability contribute to a positive outlook for Biogen's stock.
Bears say
Biogen is heavily reliant on its multiple sclerosis franchise, which faces competition and potential loss of exclusivity from biosimilars in the coming years. Its newer franchises have potential, but have faced challenges in clinical trials and there may be risks associated with their commercial success. Biogen's recent strategic initiatives may have a positive impact, but there are still uncertainties surrounding pipeline and business development. Overall, the company's outlook is negative due to these factors and the potential for decreased cash flows in the future.
This aggregate rating is based on analysts' research of Biogen and is not a guaranteed prediction by Public.com or investment advice.
Biogen (BIIB) Analyst Forecast & Price Prediction
Start investing in Biogen (BIIB)
Order type
Buy in
Order amount
Est. shares
0 shares